AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 94 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $398,116 | +55.3% | 883,720 | 0.0% | 0.07% | +32.1% |
| Q1 2023 | $256,279 | -35.5% | 883,720 | 0.0% | 0.05% | -38.4% |
| Q4 2022 | $397,586 | -14.5% | 883,720 | 0.0% | 0.09% | -20.4% |
| Q3 2022 | $465,000 | +4.3% | 883,720 | 0.0% | 0.11% | -9.2% |
| Q2 2022 | $446,000 | -78.1% | 883,720 | 0.0% | 0.12% | -76.8% |
| Q1 2022 | $2,033,000 | -51.6% | 883,720 | 0.0% | 0.51% | -37.1% |
| Q4 2021 | $4,198,000 | -40.3% | 883,720 | 0.0% | 0.81% | -26.1% |
| Q3 2021 | $7,026,000 | +14.2% | 883,720 | 0.0% | 1.10% | +45.2% |
| Q2 2021 | $6,151,000 | -12.1% | 883,720 | 0.0% | 0.76% | -41.2% |
| Q1 2021 | $6,999,000 | +0.6% | 883,720 | 0.0% | 1.29% | +84.7% |
| Q4 2020 | $6,955,000 | +11.0% | 883,720 | 0.0% | 0.70% | -60.0% |
| Q3 2020 | $6,266,000 | -30.0% | 883,720 | -8.7% | 1.75% | -39.3% |
| Q2 2020 | $8,949,000 | – | 967,500 | – | 2.88% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Yu Fan | 112,044 | $532,000 | 6.17% |
| Aisling Capital Management LP | 1,691,151 | $8,033,000 | 2.83% |
| Bain Capital Life Sciences Investors, LLC | 2,847,689 | $13,527,000 | 1.07% |
| GREAT POINT PARTNERS LLC | 910,251 | $4,324,000 | 0.96% |
| Samsara BioCapital, LLC | 883,720 | $4,198,000 | 0.81% |
| Sio Capital Management, LLC | 498,500 | $2,368,000 | 0.71% |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,167,000 | 0.53% |
| Nantahala Capital Management | 2,813,560 | $13,364,000 | 0.47% |
| Altium Capital Management LP | 293,764 | $1,395,000 | 0.38% |
| Lion Point Capital, LP | 300,000 | $1,425,000 | 0.38% |